Introduction: Erectile dysfunction (ED) in men increases with age, as does cardiovascular disease (CVD). Major risk factors of CVD are similar to ED, including insulin resistance (IR) and metabolic syndrome (MS). Hypogonadism has been associated with MS and IR in general populations.
Aim: To determine the association between hypogonadism and MS and/or IR in men with ED, and to determine if hypogonadism is related to these cardiovascular (CV) risks.
Main Outcome Measures: To compare the mean testosterone levels in men with and without IR and MS, and to show the difference in hypogonadism prevalence in mutually exclusive definitions of MS.
Methods: Mean testosterone for the National Cholesterol Education Program (NCEP) and the World Health Organization (WHO) criteria of MS were calculated using independent t-tests. Multiple range t-tests were used to compare and contrast four groups: (i) only NCEP-Third Adult Treatment Panel criteria; (ii) only the WHO criteria; (iii) men with no MS; and (iv) men fulfilling both MS definitions. Chi-squared analysis was employed to determine the association of hypogonadism with IR.
Results: The prevalence of IR was 79% and of MS was 35 % by the WHO but 43% by the NCEP. Differences in point prevalences were negligible when mutually exclusive groups of MS were compared. Mean free testosterone was lower for the WHO MS or the WHO and NCEP MS (P = 0.04) but not for only the NCEP MS criteria. IR was significantly associated with low free testosterone and hypogonadism (P = 0.02 for each). If more than one criteria were present for either the WHO or NCEP MS, free testosterone was lower (P = 0.02).
Conclusion: MS and IR are strongly associated with lower testosterone and hypogonadism. The WHO criteria are a more sensitive indicator of MS and may predict ED better. Men with ED should not only have CV risks evaluated, but should also have testosterone levels drawn.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1743-6109.2007.00530.x | DOI Listing |
BMJ Nutr Prev Health
August 2024
Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Background: Subjects with metabolic syndrome and obesity have higher levels of inflammation with depression of the vitamin D (VD) hydroxylase/metabolising genes () required to convert VD consumed in the diet into 25(OH)VD. Compared with total 25(OH)VD levels, measurement of bioavailable 25(OH)VD is a better method to determine the beneficial effect of VD.
Objective: This study investigates whether cosupplementation with VD and L-cysteine (LC), which downregulates inflammation and upregulates VD-regulating genes, provides a better therapeutic benefit than supplementation with VD-alone in African Americans (AA).
Int Ophthalmol
January 2025
University of Pittsburgh, UPMC Eye Center, 203 Lothrop Street, Pittsburgh, PA, 15213, USA.
Purpose: To analyze levels of salivary steroids, including 17-OH-progesterone (17-OHP), androstenedione, dehydroepiandrosterone, cortisol, cortisone, progesterone, testosterone, and estradiol, in patients with acute central serous chorioretinopathy (CSCR) patients.
Methods: Acute CSCR patients and healthy individuals were included in this observational case-control study. Levels of salivary steroids were determined by high-performance liquid chromatography with tandem mass spectrometry detection.
Eur J Drug Metab Pharmacokinet
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.
View Article and Find Full Text PDFJ Mol Histol
January 2025
Clinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP).
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University (Chongqing Health Center for Women and Children), Chongqing, China.
Context: PCOS pregnancies are linked to metabolic disorders affecting maternal and fetal outcomes, with maternal metabolites differing from those in normal pregnancies.
Objective: To investigate the metabolic communication at the maternal-fetal interface in PCOS pregnancies.
Design: Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!